Abstract. Homeobox A1 (HOXA1) serves an oncogenic role in multiple cancer types. However, the role of HOXA1 in non-small cell lung cancer (NSCLC) remains unclear. In the present study, use of reverse transcription-quantitative polymerase chain reaction and the databases of The Cancer Genome Atlas (TCGA), Oncomine, Gene Expression Profiling Interactive Analysis and the Multi Experiment Matrix were combined to assess the expression of HOXA1 and its co-expressed genes in NSCLC. Bioinformatic analyses, such as Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and network and protein-protein interaction analyses, were used to investigate the underlying molecular mechanism effected by the co-expressed genes. Additionally, the potential miRNAs targeting HOXA1 were investigated.
Introduction
According to the latest data, lung cancer is the most common cancer worldwide and a leading cause of tumor-related mortality (1, 2) . Lung cancer causes almost 1.4 million mortalities each year all over the world (3, 4) . According to histological type, lung cancer is divided into two categories: Small-cell lung cancer (SCLC) and non-SCLC (NSCLC). NSCLC makes up 80-85% of all lung cancer cases (5) . The majority of the newly diagnosed NSCLC cases are at an advanced stage, with a low 5-year survival rate (6) . Hence, it is worthwhile to investigate the possible molecular mechanisms involved in NSCLC tumorigenesis and progression.
HOXA1, also known as BSAS, HOX1 or HOX1F, serves vital roles in multiple cancer types, including cervical, breast and esophageal cancer (7) (8) (9) . HOXA1 is involved in the proliferation, migration and invasion of different cancer types, including esophageal cancer (9) , prostate cancer (10) and NSCLC (11). Zhan et al (11) found that HOXA1 could act as the direct target Li et al (9) found that the high expression of miR-30b could downregulate HOXA1 to inhibit the growth, migration and invasion of esophageal cancer cells. Several studies have shown the clinical role of HOXA1 in NSCLC. For example, Zha et al (12) found that HOXA1 was overexpressed in hepatocellular carcinoma (HCC), and high HOXA1 expression was positively associated with the T classification, N classification, distant metastasis and the clinical stage of HCC patients. Additionally, the overexpression of HOXA1 associated with a shorter overall survival time. Yuan et al (13) found that HOXA1 expression was positively associated with the development and clinical prognosis of gastric cancer. These findings suggest that HOXA1 could act as a novel prognostic biomarker in gastric cancer. The present study sought to investigate the expression of HOXA1 in NSCLC and normal lung tissue based on reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Furthermore, The Cancer Genome Atlas (TCGA), Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA) and Multi Experiment Matrix (MEM) databases were used to assess the expression and the clinical role of HOXA1 in NSCLC. Bioinformatic analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), network and protein-protein interaction (PPI) analyses, were implemented to investigate the potential functions, pathways and networks of the co-expressed genes (14) (15) (16) . Additionally, 12 miRNA target prediction algorithms were applied to predict the potential miRNAs targeting HOXA1.
Materials and methods

RT-qPCR.
A total of 53 NSCLC patients, including 31 lung adenocarcinoma (LUAD) patients and 22 lung squamous cell carcinoma (LUSC) patients, were enrolled from the Department of Pathology, First Affiliated Hospital of Guangxi Medical University (Nanning, Guangxi, China). All 53 samples were randomly collected from patients undergoing surgical resection without treatment. All methods were applied according to the relevant guidelines. The Ethics Committee of the First Affiliated Hospital of Guangxi Medical University approved the experimental protocols, and all patients provided written informed consent forms for the use of their tissues in this study. Total RNA was extracted via TRIzol reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA), and a PCR amplification kit (Omega, Solarbio Biotechnologies, Inc., Shanghai, China) was used. The RNA was reverse-transcribed into cDNA using Roche cDNA Synthesis kit (Roche Diagnostics, Shanghai, China), based on the manufacturer's protocols. qPCR was performed using ABI 7500 prepstation (Applied Biosystems; Thermo Fisher Scientific, Inc.), and the SYBR ® -Green PCR Master mix (GeneCore Biotechnologies, Inc., Shanghai, China). PCR was performed at 95˚C for 15 sec, 60˚C for 1 min, 95˚C for 15 sec and 60˚C for 1 min for 40 cycles. The specific primers were as follows: HOXA1 forward, 5'-CGGCTTCCTGTGCTAAGTCT-3' and reverse, 5'-TAGCCCAGCCAAATACACGG-3'; and GAPDH (internal control) forward, 5-'TGCACCACCAACTGCTTA-3' and reverse, 5'-GGATGCAGGGATGATGTTC-3'. The results were normalized to the GAPDH expression and calculated based on the 2 -∆∆Cq method (17, 18) . One-way analysis of variance was applied to compare different subgroups. The Mann-Whitney U test or Kruskal-Wallis H test was utilized for non-normally distributed variables. The associations between HOXA1 expression and miRNA expression were assessed by Spearman's correlation. Mining for co-expressed genes across hundreds of datasets was performed through novel rank aggregation and visualization methods. Two-sided P-values of <0.05 were identified to indicate statistical significance.
Results
Clinical value of HOXA1 expression in NSCLC.
In the present study, HOXA1 mRNA was overexpressed in NSCLC compared with that in normal lung tissues (P=0.011; Fig. 1A ).
The associations between the expression of HOXA1 and different clinicopathological parameters were further investigated. HOXA1 expression was positively associated with advanced (stage III-IV) TNM, Tumor-Node-Metastasis (TNM) classification of malignant tumors (26) and presence of lymph node metastasis (LNM) (both P<0.001; Fig. 1B and C). No significant association was found between HOXA1 mRNA expression and any other clinicopathological parameter, including sex, tumor size and vascular invasion (Table I ). In addition, the diagnostic value of the HOXA1 level in NSCLC was assessed by ROC curve, and the area under the curve (AUC) of HOXA1 was 0.656 [95% confidence interval (CI), 0.552-0.761; P=0.005; Fig. 1D ). The expression of HOXA1 was also compared between LUAD and LUSC. The results were similar to those of NSCLC: HOXA1 was upregulated in LUSC (P=0.012; Fig. 2A ), and HOXA1 expression was positively associated with the presence of LNM and an advanced TNM stage (Ⅲ-Ⅳ, both P<0.05) in LUAD and LUSC ( Fig. 2B-2E ; Tables II and III To further research the differential expression of HOXA1 between NSCLC and non-cancerous lung tissues, original patient data was obtained from TCGA. Two NSCLC cohorts, which comprised i) 535 LUAD cases and 59 normal lung cases, and ii) 502 LUSC cases and 49 normal lung cases, were extracted. As a result, increased expression of HOXA1 was observed in LUAD and LUSC compared with that in normal lung tissues (both P<0.05; Fig. 3A and B) . Regarding the clinicopathological parameters, no statistical significance was reached based on the TCGA database (Tables IV and V) . The AUC of HOXA1 was 0.548 (95% CI, 0.498-0.599; P=0.002) for LUAD and 0.957 (95% CI, 0.940-0.974; P<0.001) for LUSC based on TCGA, which indicated a high diagnostic value of the HOXA1 level in LUSC (Fig. 3C and D) . With regard to overall survival, no statistical significance was determined; a trend was observed in which low HOXA1 expression was associated with an increased survival time (97.11±11.49 months) compared with high HOXA1 expression (75.15±9.68 months) (P=0.098; Fig. 3E ) in LUAD, and the opposite trend was noted in LUSC (P=0.795; Fig. 3F ), indicating that high HOXA1 expression may be associated with increased survival time of NSCLC patients.
A total of 11 datasets [Hou Lung, Wachi Lung, Beer Lung, Stearman Lung, Garber Lung, Landi Lung, Bhattacharjee Lung, Su Lung, Talbot Lung, Selamat Lung and Okayama Lung (22) ] in Oncomine were used to validate the HOXA1 expression. Bhattacharjee Lung showed an opposite trend to all other datasets, as HOXA1 expression was downregulated compared with Table IV . Expression of HOXA1 and associations with clinicopathological parameters in LUAD based on The Cancer Genome Atlas. that in the normal lung. The results from the other 10 datasets were consistent with the present RT-qPCR and TCGA findings ( Fig. 4A and B) . GEPIA was used to further confirm the high expression of HOXA1 in LUAD and LUSC compared with that in the non-cancerous lung tissues (Fig. 4C and D) .
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Potential pathways associated with HOXA1. Based on GEPIA, TCGA and MEM, 1,264 overlapping co-expressed genes were selected (Fig. 5) for GO and KEGG pathway analyses. The strongly enriched GO functional terms were 'dGTP metabolic process', 'network-forming collagen trimer' and 'centromeric DNA binding' (Fig. 6 ; Table VI ). The KEGG pathway most strongly associated with the HOXA1 co-expressed genes was 'the p53 signaling pathway' (Table VII) . Altogether, the GO and KEGG pathway analyses indicated that HOXA1 may be associated with the biological mechanism of NSCLC.
A PPI network was constructed via STRING online, and a total of 3,250 PPI pairs with a combined score of >0.4 were noted. The map of the PPI network that involved 908 PPI pairs was chosen for further analysis, and its connectivity degree was >30 (Fig. 7) . Trifunctional purine biosynthetic protein adenosine-3 (GART; degree=71) had the highest degree and most interactions, according to the PPI network.
A total of 17 genes (ZMAT3, CYCS, CHEK1, CDK6, SFN, SESN3, CCNB1, CCNE1, TP53I3, CDKN2A, CCNB2, CCND2, SERPINB5, DDB2, PERP, IGFBP3 and GADD45A) associated with the p53 signaling pathway were flagged by KEGG pathway analysis, and 4 genes (CDKN2A, RAD51, CHEK1 and GART) had a degree of connectivity of >50 in the PPI network. The genes shared in common by these two lists were cyclin-dependent kinase inhibitor 2A (CDKN2A) and checkpoint kinase 1 (CHEK1). The expression of the two genes in the original TCGA data was investigated and it was found that each was highly expressed in LUAD and LUSC compared with that in normal lung tissues (both P<0.001; Fig. 8A-D) .
Based on these results, we hypothesized that HOXA1 serves a vital role in NSCLC by co-expressing with CDKN2A and CHEK1.
Prediction of target miRNAs. In the present study, 12 target prediction algorithms were used to predict the potential miRNAs that targeted HOXA1. The miRNAs predicted by >10 algorithms were selected as the final candidate miRNAs. A total of 3 miRNAs (miR-181b-5p, miR-28-5p, miR-181d-5p) targeting HOXA1 were predicted by the 10 algorithms. Based on TCGA, miR-181b, miR-28 and miR-181d levels were found to be significantly upregulated in LUAD compared with those in non-cancerous lung tissues (all P<0.05; Fig. 9A-C) . miR-181b and miR-181d levels were found to be significantly downregulated in LUSC, whereas miR-28 level was found to exhibit no significant difference in LUSC and normal lung tissues ( Fig. 9D-F) . Furthermore, the correlation between HOXA1 and these three miRNAs in NSCLC was compared using Spearman-test based on TCGA, and it was found that HOXA1 mRNA level was inversely correlated with miR-181b and miR-181d in both LUAD and LUSC (both P<0.05; Table VIII ). However, miR-28 level was inversely correlated with HOXA1 mRNA level in LUAD (r=-0.010, P=0.827) and positively correlated in LUSC (r=0.057, P=0.216) (Table VIII) . Since miR-181b and miR-181d expression was downregulated in LUSC tissues and inversely correlated with HOXA1 expression, we speculate that HOXA1 may be the direct target of miR-181b-5p or miR-181d-5p in LUSC, and may serve a significant role in NSCLC by regulating various pathways, particularly the p53 signaling pathway. However, the detailed mechanism should be verified by functional experiments.
Discussion
In the present study, RT-qPCR, TCGA, MEM, Oncomine and GEPIA were used to investigate the expression, clinical significance and possible functions or pathways of HOXA1 Figure 6 . A functional network of GO terms for the genes co-expressed with homeobox A1 in non-small cell lung cancer. GO analysis was performed using the overlapping genes, and a functional network was constructed to further reflect the functions of these genes. GO, Gene Ontology.
in NSCLC. It was found that HOXA1 was overexpressed in NSCLC based on the RT-qPCR, TCGA and GEPIA data. The ROC curve was utilized to evaluate the association between HOXA1 expression and diagnostic value, and the AUC of HOXA1 confirmed the moderate diagnostic value of HOXA1 in NSCLC. HOXA1 was confirmed as a tumorigenic gene, and high HOXA1 expression was associated with TNM stage and LNM. According to GO and KEGG analyses, the strongly enriched GO functional terms were 'dGTP metabolic process', 'network-forming collagen trimer' and 'centromeric DNA binding', and the HOXA1 co-expressed genes were significantly associated with 'the p53 signaling pathway'. Several studies have investigated the effect of HOXA1 in NSCLC. Abe et al (27) detected the expression levels of 39 HOX genes in 41 human NSCLC and normal lung tissues by RT-qPCR, and found that HOXA1 was highly expressed in NSCLC tissues and was upregulated in LUSC compared Figure 7 . PPI network of the co-expressed genes. The PPI network was constructed via the Search Tool for the Retrieval of Interacting Genes online, and 908 PPI pairs with a connectivity degree of >30 were chosen for further analysis. PPI, protein-protein interaction. with that in LUAD. Similarly, the present study quantified the HOXA1 expression level in 53 NSCLC tissues and 53 normal lung tissues and found similar results on HOXA1 expression. Additionally, these expression findings were verified via other databases and the molecular mechanisms of HOXA1 action were predicted by GO and KEGG analyses. Abe et al (27) hypothesized that HOX genes are involved in the histologically aberrant diversity, which would explain the different HOXA1 expression in LUAD and LUSC. Zhan et al (11) found that HOXA1 could act as the direct target of let-7c in NSCLC, and that let-7c could inhibit the proliferation and tumorigenesis of NSCLC cells via partial targeting of HOXA1. The present study found that miR-181b and miR-181d were downregulated in LUSC tissues and that HOXA1 mRNA expression was inversely correlated with miR-181b and miR-181d levels based on TCGA. We speculate that HOXA1 may be the direct target of miR-181b-5p or miR-181d-5p in LUSC and that it may serve a significant role in NSCLC in combination with these miRNAs. However, the detailed mechanism of its activity should be verified by functional experiments. Based on KEGG analysis, the p53 signaling pathway was the most strongly enriched pathway term. The p53 signaling pathway could serve a vital role in NSCLC, but no studies on HOXA1 and p53 signaling could be found in the global literature. Liu et al (28) found that p53 was the most commonly mutated gene in NSCLC, being mutated in 45-70% of LUAD samples and 60-80% of LUSC samples. Normally, p53 is located in the cytoplasm, but it translocates to the nucleus following phosphorylation by various kinases upon cellular stress (29) . Phosphorylated nuclear p53 binds to different proteins to stimulate apoptosis (30) (31) (32) . In addition to its effect on apoptosis, several studies have demonstrated the effect of p53 signaling on proliferation, migration, invasion and prognosis (33) (34) (35) . We hypothesized that HOXA1 serves a significant role in NSCLC via the p53 signaling pathway, but the detailed mechanism of HOXA1 in NSCLC requires determining. To test this hypothesis, we plan to apply a variety of approaches, including cell proliferation, migration, invasion and apoptosis assays, and animal models, in future studies. The clinical significance and the molecular mechanism of HOXA1 in the biological function of NSCLC will be investigated at the molecular, cellular, tissue and animal levels. The findings of the present study with regard to HOXA1 provide a novel biomarker or therapeutic target for NSCLC.
